Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease

Stock Information for Serina Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Serina Therapeutics Inc.

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Serina Therapeutics Appoints Farrell Simon to its Board of Directors
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.